ICON Completes Acquisition of Aptiv Solutions
08 Maio 2014 - 7:00AM
Business Wire
ICON plc, (NASDAQ: ICLR), a global provider of outsourced
development services to the pharmaceutical, biotechnology and
medical device industries, today announced that it has completed
the previously announced acquisition of Aptiv Solutions.
Aptiv Solutions is a recognised leader in the design and
execution of adaptive clinical trials for pharmaceutical and
biotech customers. The company also has in-depth experience in the
management of medical device trials and its Japanese subsidiary,
Niphix, is a full-service, oncology-focused CRO serving both
Japanese and international customers.
“Aptiv’s adaptive trial capabilities, combined with our existing
technology platforms, such as ICONIK and Firecrest, will further
differentiate our services and help our customers take time and
cost out of the development process,” commented Dr. Nuala Murphy,
President, ICON Clinical Research Services. “Their presence in
Japan and medical device capabilities will also broaden our
offerings in these markets.”
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has approximately 10,300 employees, operating from 76 locations in
37 countries.
Further information is available at www.iconplc.com
ICON/ICLR-F
ICONBrendan BrennanChief Financial Officer+
353-1-291-2000orSimon HolmesEVP Investor Relations & Corporate
Development+ 353-1-291-2000
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024